FDA Warning Letter Will Not Affect Repel-CV PMA, SyntheMed CEO Says
This article was originally published in The Gray Sheet
Executive Summary
An FDA warning letter to SyntheMed will not affect the company's pending PMA for its Repel-CV cardiac surgery adhesion barrier, CEO Robert Hickey says